Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics

Oncotarget

Volumn 8, Issue 30, 2017, Pages 48794-48806

  Engert, Florian ^a,b   Kovac, Michal ^c   Baumhoer, Daniel ^c   Nathrath, Michaela ^d,e,f   Fulda, Simone ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f KLINIKUM KASSEL   (Germany)

Author keywords

Apoptosis; Cell death; Osteosarcoma; PARP inhibitor; PARP1

Indexed keywords

ANTINEOPLASTIC AGENT; ATM PROTEIN; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; CARBOPLATIN; CASPASE; CASPASE INHIBITOR; CELL DNA; CHECKPOINT KINASE 2; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FANCONI ANEMIA GROUP D2 PROTEIN; FIRTECAN; METHOTREXATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAK; PROTEIN BAX; TALAZOPARIB; TEMOZOLOMIDE; BAK1 PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHTHALAZINE DERIVATIVE;

ALLELE; APOPTOSIS; ARTICLE; ATM GENE; BAP1 GENE; BARD1 GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL VIABILITY; CHEK2 GENE; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG POTENCY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; FANCD2 GENE; GENE; GENE DISRUPTION; GENE MUTATION; GENE SILENCING; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; HETEROZYGOTE; HUMAN; HUMAN CELL; MG63 CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; MNNG HOS CELL LINE; MOLECULAR GENETICS; MUTANT; OSTEOSARCOMA CELL; PHARMACOGENETICS; PTEN GENE; RECOMBINATION REPAIR; SAOS-2 CELL LINE; TUMOR SUPPRESSOR GENE; U2OS CELL LINE; ZK 58 CELL LINE; BONE TUMOR; CELL SURVIVAL; DRUG EFFECT; GENETICS; METABOLISM; OSTEOSARCOMA; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BONE NEOPLASMS; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DOXORUBICIN; DRUG SYNERGISM; GENES, BRCA1; GENES, BRCA2; HUMANS; OSTEOSARCOMA; PHTHALAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS;

EID: 85025843117     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10720     Document Type: Article

References (35)

1. Zhu L, McManus MM, Hughes DPM. Understanding the biology of bone sarcoma from early initiating events through late events in metastasis and disease progression. Frontiers in Oncology. 2013; 3: 230.
2. Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment-where do we stand? A state of the art review. Cancer Treat Rev. 2014; 40: 523-532.
3. Kovac M, Blattmann C, Ribi S, Smida J, Mueller NS, Engert F, Castro-Giner F, Weischenfeldt J, Kovacova M, Krieg A, Andreou D, Tunn PU, Durr HR, et al. Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. Nat Commun. 2015; 6: 8940.
4. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010; 10: 293-301.
5. Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med. 2013; 19: 1381-1388.
6. Lord CJ, Tutt AN, Ashworth A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu Rev Med. 2015; 66: 455-470.
7. O'Connor MJ. Targeting the DNA Damage Response in Cancer. Mol Cell. 2015; 60: 547-560.
8. Liu JF, Matulonis UA. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment? Curr Oncol Rep. 2016; 18: 29.
9. Helleday T. PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations. Ann Oncol. 2016; 27: 755-757.
10. Shen Y, Aoyagi-Scharber M, Wang B. Trapping Poly(ADPRibose) Polymerase. J Pharmacol Exp Ther. 2015; 353: 446-457.
11. Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, Morris J, Teicher B, Doroshow JH, Pommier Y. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2014; 13: 433-443.
12. Fulda S. Tumor resistance to apoptosis. Int J Cancer. 2009; 124: 511-515.
13. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006; 25: 4798-4811.
14. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov. 2010; 9: 447-464.
15. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014; 15: 49-63.
16. Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, Lu KH, Chen J, Tran TV, Williams D, Iliev D, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012; 107: 1776-1782.
17. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70: 440-446.
18. De Bono J, Mina L, Gonzalez M, Curtin N, Wang E, Henshaw J, Chadha M, Sachdev J, Matei D, Jameson G, Ong M, Basu B, Wainberg Z, et al. First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. J Clin Oncol 31, 2013 (suppl; abstr 2580). 2013;
19. Smith MA, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Kurmasheva RT, Wheeler DA, et al. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatr Blood Cancer. 2015; 62: 91-98.
20. Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016; 16: 110-120.
21. Shen WH, Balajee AS, Wang J, Wu H, Eng C, PandolfiPP, Yin Y. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007; 128: 157-170.
22. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ, Ashworth A. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med. 2009; 1: 315-322.
23. Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJ, Smith G, Powell JE, Rudzki Z, Kearns P, Moss PA, Taylor AM, Stankovic T. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood. 2010; 116: 4578-4587.
24. Li M, Yu X. Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation. Cancer Cell. 2013; 23: 693-704.
25. Lee JS, Collins KM, Brown AL, Lee CH, Chung JH. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature. 2000; 404: 201-204.
26. Kim H, D'Andrea AD. Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev. 2012; 26: 1393-1408.
27. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006; 66: 8109-8115.
28. Horton JK, Wilson SH. Strategic Combination of DNADamaging Agent and PARP Inhibitor Results in Enhanced Cytotoxicity. Front Oncol. 2013; 3: 257.
29. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012; 72: 5588-5599.
30. Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, Liu M, Lonigro R, Prensner JR, Tomlins SA, Chinnaiyan AM. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res. 2012; 72: 1608-1613.
31. Norris RE, Adamson PC, Nguyen VT, Fox E. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors. Pediatr Blood Cancer. 2014; 61: 145-150.
32. Sonnenblick A, de Azambuja E, Azim HA, Jr., Piccart M. An update on PARP inhibitors-moving to the adjuvant setting. Nat Rev Clin Oncol. 2015; 12: 27-41.
33. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, Quarterman CP, Hoffman R, Stevens MF, Brampton MH, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992; 65: 287-291.
34. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 1997; 57: 3823-3829.
35. Chou TC. (1991). The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TC, ed. Synergism and antagonism in chemotherapy. (San Diego, USA: Academic Press), pp. 61-102.